During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Giuseppe Gritti, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?